SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Solid Biosciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.92+0.39 (+7.05%)
Close on Oct 19, 2026
- Market cap
- $850.64M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Operating margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | – | |
| Return on assets | – | – | – | |
| Current ratio | – | 6.49 | 6.14 | |
| Interest coverage | – | – | 882.8× | |
| Capex to revenue | – | – | – | |
| Diluted shares | 0M | 3M | 88M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Solid Biosciences generated $526.22M from operations and spent $7.62M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$526.22M
Used
$7.62M
Capital expenditure$7.62M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 3 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$156.29M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$156.29M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.20 → 6.14
- No dilutionShare count did not rise41M → 88M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –